CN1231224C - Sealwort polysaccharide konjaku glucomannan capsule - Google Patents
Sealwort polysaccharide konjaku glucomannan capsule Download PDFInfo
- Publication number
- CN1231224C CN1231224C CN 98121819 CN98121819A CN1231224C CN 1231224 C CN1231224 C CN 1231224C CN 98121819 CN98121819 CN 98121819 CN 98121819 A CN98121819 A CN 98121819A CN 1231224 C CN1231224 C CN 1231224C
- Authority
- CN
- China
- Prior art keywords
- capsule
- glucomannan
- polygonatum polysaccharide
- polysaccharide
- polygonatum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a polygonatum polysaccharide konjak glucomannan partial hydrolysate capsule. The present invention is a capsule prepared from a bioactivity component, namely polygonatum polysaccharide and konjak glucomannan partial hydrolysate as main components, wherein the polygonatum polysaccharide is prepared by extracting and separating a traditional Chinese medicine, namely rhizoma polygonati through modern biochemical technologies; the konjak glucomannan partial hydrolysate is prepared by degrading and separating refined konjak powder as raw materials through biological or chemical methods; the capsule has the obvious functions of delaying aging, improving memory ability, regulating blood fat and preventing constipation. The capsule has no toxic and side effect, and can regulate immunity, restore qi, benefit vital energy, strengthen vitality, prolong life, improve memory ability, regulate blood fat and prevent constipation.
Description
The present invention relates to a kind of effective active composition polygonatum polysaccharide that extracts with the Chinese medicine Rhizoma Polygonati, and be that the Rhizoma amorphophalli glucomannan partial hydrolystate that the raw material degraded forms is the capsule that main component prepares with konjaku powder.
Rhizoma Polygonati (Ploygonatum) is one of Chinese medicine, and the beginning is stated from Mingyi Bielu, and tool the kidney invigorating and essence nourishing, nourshing Yin and drynsessmoistening prescription merit are used for nourishing and fit keeping function and treatment deficiency of kidney essence, and the card of deficiency of the lung cough caused by dryness and weakness of the spleen and stomach has very long history, is one of traditional Chinese medical science common drug.The Mingyi Bielu record: Rhizoma Polygonati " sweet in the mouth, flat, nontoxic.Main invigorating the spleen and replenishing QI removes rheumatism, settling five organs.For a long time clothes make light of one's life by commiting suicide prolong life not hungry." Compendium of Materia Medica carries: " and Rhizoma Polygonati is for taking key medicine, so Lu not list in first of the careless portion, celestial family thinks ZHICAO and so on, with its female scholar's essence, so the Rhizoma Polygonati of meaning." angle's ZHICAO is through being loaded with: " and Rhizoma Polygonati alleviating distention in middle-JIAO QI invigorating, it is good that the five internal organs are transferred, muscle sufficiency, bone marrow is strong, and its power increases doubly, and is not old for many years, color clear, it is more black to turn white, and dedentition is more living." modern pharmacology studies have shown that Rhizoma Polygonati has enhance immunity, blood sugar lowering, blood fat, effects such as slow down aging.Polygonatum polysaccharide is an important active component of Rhizoma Polygonati biological active agents, pharmaceutical research proves, polygonatum polysaccharide has immune stimulating, enhancing immunity, slow down aging, leukocyte increasing, anti peroxidation of lipid significantly improves the SOD activity, significantly reduces the heart, liver, kidney lipofuscin content, obviously suppress the activity of monoamine oxidase B (MAO--B), prolong effects such as laboratory animal life-span.
Rhizoma amorphophalli glucomannan is the active dietary fiber of a kind of tool various biological, modern pharmacology studies have shown that, having the body's cholesterol of inhibition rises, lipidemia, blood sugar regulation, prevent constipation, colon cancer and associated hemorrhoid lower serum cholesterol content, the effects such as heart disease that prevention is caused by coronary atherosclerosis.The pharmaceutical research of Rhizoma amorphophalli glucomannan partial hydrolystate shows that except that above-mentioned dietary fiber function, still a kind of bifidobacterium growth factor by profitable strain utilizations such as bacillus bifiduss, promotes the propagation of bacillus bifidus in intestinal.
Based on above-mentioned, the objective of the invention is with polygonatum polysaccharide and Rhizoma amorphophalli glucomannan partial hydrolystate is main component, makes a kind of tool slow down aging, improves memory, blood lipid regulation, the oral health-caring capsule of prevent constipation.
Key problem in technology of the present invention and scheme are: adopt biochemical technology, extraction separation goes out polygonatum polysaccharide from the Chinese medicine Rhizoma Polygonati; Adopt biological or chemical method degraded konjaku powder, through separate, concentrate, operation such as drying is prepared into the Rhizoma amorphophalli glucomannan partial hydrolystate; With polygonatum polysaccharide and Rhizoma amorphophalli glucomannan partial hydrolystate is primary raw material, mixes fillers such as adding starch again according to a certain ratio, and preparation technology makes oral capsule through capsule manufacture.
Detailed content of the present invention:
One, the preparation of polygonatum polysaccharide
1, crude drug.The Rhizoma Polygonati crude drug goes mouldy to select not have, the color Huang is pure, do not have assorted assorted Chinese medicine Rhizoma Polygonati tuber is raw material." the Rhizoma Polygonati kind (Rhizoma Polygonati polygonatum sibiricum Red., Polygonatum cyrtonema Hua P.cyrtonema Hua Yunnan Rhizoma Polygonati P.kingianum Coll.et Hemsl) recorded of Chinese pharmacopoeia all can.
2, washes clean, section.
3, dry (available drying plant etc. are dried to water content about 12% and are advisable) is ground into fine grained.
4, alcohol reflux.Rhizoma Polygonati crude drug after pulverizing is dropped in the reflux vessel, carry out reflow treatment, remove small-molecule substances such as pigment with high concentration ethanol (ethanol more than 70%).
5, filtration, lixiviate.Available filter (also available centrifugation apparatus) filters, and gets filtering residue for lixiviate polygonatum polysaccharide usefulness, and ethanol reclaims distillation back reuse.With ethanol (20-40%) the lixiviate filtering residue of debita spissitudo, extract the bioactive polygonatum polysaccharide of tool, lixiviating solution is standby.
6, precipitate with ethanol.(60-90%) separates out polygonatum polysaccharide with high concentration ethanol.The polygonatum polysaccharide that centrifugal collection is separated out, the ethanol supernatant distillation of high concentration is reclaimed.Also can adopt evaporating concentrating method to collect polygonatum polysaccharide.
7, drying.Can adopt multiple drying means to carry out the drying of polygonatum polysaccharide.As lyophilization, oven dry below 60 ℃ etc.
Two, the preparation of Rhizoma amorphophalli glucomannan partial hydrolystate
1, the part of konjaku powder degraded.Adopt the biological enzyme konjaku powder of partly degrading, selected enzyme such as cellulase, konjak portuguese gansu polyose carbohydrase, hemicellulase etc.Consider that the swelling solution viscosity after the konjaku powder swelling is very big, enzymatic degradation liquid is unsuitable feeding-up, is advisable with 5-10%.Also can adopt the chemical method konjaku powder of partly degrading.
2, separate, extract.Part degradation product with centrifuge centrifugalize konjaku powder and Rhizoma amorphophalli glucomannan.Precipitate the konjaku powder of part, collect to give over to when degrading next time and use for not being degraded as yet.Centrifugal top section is the part degradation product of Rhizoma amorphophalli glucomannan.
3, concentrate.Concentrate konjak portuguese gansu polyose sugar moieties degradation product with the negative pressure concentrator, get final product to solid content＞20%.
4, drying.Rhizoma amorphophalli glucomannan partial hydrolystate after available spray drying device drying concentrates obtains Rhizoma amorphophalli glucomannan partial hydrolystate powder.
Three, the pharmacology of major function composition and physiological function
(1), the pharmacological function of polygonatum polysaccharide:
1, prolong the laboratory animal life-span: polygonatum polysaccharide can prolong average life and the maximum life span for female, the male both sexes fruit bat of examination, and experimental result has significant difference.
2, anti-senescence function: polygonatum polysaccharide is to the active lymphocyte percentage of old rats ANAE, erythrocyte, crystal nuclear, lens cortex superoxide dismutase activity, liver and kidney lipofuscin content, heart lipid peroxide content, the monoamine oxidase B activity effect that all has clear improvement in the brain compares with the distilled water matched group that there were significant differences.
3, raise immunity: polygonatum polysaccharide can obviously promote the weight of normal mouse thymus and spleen to increase, and obviously strengthens the speed of cleaning up of mouse vein injecting glue body carbon granules, and mice reticuloendothelial system phagocytic function is had obvious activation.
4, nootropics function: polygonatum polysaccharide can obviously improve old rats learning and memory and memory represents ability.
5, human body is had no side effect.
(2), the physiology of Rhizoma amorphophalli glucomannan partial hydrolystate and pharmacological function:
1, blood lipid regulation effect.
2, reduce diabetes patient's blood glucose.
3, relieving constipation improves constipation.
4, the bifidobacterium growth factor promotes the growth and the breeding of bacillus bifidus, thereby is a kind of new functional oligose.
5, human body is had no side effect.
Four, main components in percentage by weight of the present invention:
Polygonatum polysaccharide 1------20%
Rhizoma amorphophalli glucomannan partial hydrolystate 40-----80%
Filler 5------30% such as starch
Five, industrialized producing technology flow process of the present invention is:
The Rhizoma Polygonati crude drug is through cleaning, cut into slices, dry, pulverize, refluxing, and filtration, extraction, ethanol precipitation, dehydrate get polygonatum polysaccharide; Konjaku powder separates, extracts after the part degraded, gets konjak portuguese gansu polyose sugar moieties degradation product through concentrated, spray drying again.Will be through the fillers such as polygonatum polysaccharide, konjak portuguese gansu polyose sugar moieties degradation product and starch of above-mentioned technology gained, by encapsulated after the aforementioned ratio mixing.Promptly get the sealwort polysaccharide konjaku glucomannan capsule finished product.
Should illustrate, with polygonatum polysaccharide and konjak portuguese gansu polyose sugar moieties degradation product is main component, and the tool slow down aging of formation improves memory, blood lipid regulation, the compositions of prevent constipation health care changes the content ratio of this two main component, and adds suitable filler and adjuvant, but Development and Production becomes different product forms, except that capsule, just like oral liquid, tablet etc.
Embodiment: the polygonatum polysaccharide that adopts above-mentioned production technology preparation, konjak portuguese gansu polyose sugar moieties degradation product (konjak portuguese gansu polyose sugar moieties degradation product accounts for 80% for dried powder, polygonatum polysaccharide content 20%), animal drug effect and pharmacological testing and safety testing show, this compositions 250mg.kg
-1.d
-1And 500mg.kg
-1.d
-1Irritate the stomach old rats, distilled water compares, successive administration 30 days.Measure and old and feeble relevant physiological and biochemical index, the result shows: to old rats erythrocyte sod activity, and liver lipofuscin content, the effect that all has clear improvement has significant difference compared with the control.With 250mg.kg
-1.d
-1And 500mg.kg
-1.d
-1This compositions is irritated the stomach old rats, and distilled water compares, successive administration 30 days.Measure blood lipids index, the result shows that the free serum fatty acid fully changes, but neutral fat (triglyceride) reduces obviously, and takes preceding comparison, descends 20% approximately, and cholesterol also obviously descends simultaneously.With this compositions 250mg.kg
-1.d
-1And 500mg.kg
-1.d
-1Irritate the stomach old rats, negative control, the equivalent distilled water, positive control is irritated the stomach hydergine, behind the continuous irrigation stomach 15 days, with Y type labyrinth old rats is carried out learning test, measure its memory represents after 24 hours, measurement result shows, this compositions can significantly be improved old rats learning and memory and memory represents ability, reduces errors number.Compare with negative control, this compositions high dose group, low dose group, the positive are organized the errors number that utmost points has all reduced old rats significantly.Safety testing is the result show, this compositions is to the human body safe without toxic side effect.
Claims (4)
1, a kind of sealwort polysaccharide konjaku glucomannan capsule is characterized in that: this capsule be the Rhizoma amorphophalli glucomannan partial hydrolystate for preparing by the bioactive ingredients polygonatum polysaccharide that adopts biochemical technology from the Chinese medicine Rhizoma Polygonati, to extract and degraded konjaku powder be main component by a certain percentage mixing be prepared from.
2, polygonatum polysaccharide glucomannan capsule as claimed in claim 1 is characterized in that:
Polygonatum polysaccharide content: 1-20%
Rhizoma amorphophalli glucomannan partial hydrolystate content: 40-80%
Fillers such as starch: 5-30%
More than three component total amounts be 100%.
3, the manufacture method of polygonatum polysaccharide glucomannan capsule as claimed in claim 2 may further comprise the steps:
The Rhizoma Polygonati crude drug gets polygonatum polysaccharide through cleaning, section, oven dry, pulverizing, backflow, filtration, extraction, ethanol precipitation, dehydrate; Konjaku powder separates, extracts after the part degraded, gets konjak portuguese gansu polyose sugar moieties degradation product through concentrated, spray drying again; To by encapsulated after the aforementioned ratio mixing, promptly get the sealwort polysaccharide konjaku glucomannan capsule finished product through the fillers such as polygonatum polysaccharide, konjak portuguese gansu polyose sugar moieties degradation product and starch of above-mentioned technology gained.
4, polygonatum polysaccharide glucomannan capsule as claimed in claim 2 manufacturing needles to slow down aging, improve the application in memory, blood lipid regulation, the constipation medicine; The ratio of Rhizoma amorphophalli glucomannan partial hydrolystate and add other auxiliary packing and can be made into tablet, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98121819 CN1231224C (en) | 1998-10-30 | 1998-10-30 | Sealwort polysaccharide konjaku glucomannan capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98121819 CN1231224C (en) | 1998-10-30 | 1998-10-30 | Sealwort polysaccharide konjaku glucomannan capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1259348A CN1259348A (en) | 2000-07-12 |
| CN1231224C true CN1231224C (en) | 2005-12-14 |
Family
ID=5227321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 98121819 Expired - Fee Related CN1231224C (en) | 1998-10-30 | 1998-10-30 | Sealwort polysaccharide konjaku glucomannan capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1231224C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331423C (en) * | 2004-04-30 | 2007-08-15 | 南阳市海达生物技术有限公司 | Food for relaxing bowel and reducing body weight and its preparation method |
| CN101293070B (en) * | 2008-06-25 | 2010-11-10 | 河南中医学院 | Extraction of seal wort oligose with effect of reinforcing immune function from seal wort |
| CN108410666A (en) * | 2018-04-28 | 2018-08-17 | 黔西南州睿杰鹿业发展有限公司 | A kind of immersion process of deer antler wine |
| CN108936673A (en) * | 2018-05-25 | 2018-12-07 | 陕西黄龙国寿堂生物工程有限公司 | For toxin-expelling and face nourishing, the food therapeutic composition of weight-reducing and preparation method thereof |
-
1998
- 1998-10-30 CN CN 98121819 patent/CN1231224C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1259348A (en) | 2000-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1286513C (en) | Chinese medicine composition for treating dermatosis and its preparing method | |
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN103405577B (en) | The Pharmaceutical composition of a kind of enhancing immunity, fatigue alleviating | |
| CN111686147A (en) | Eucommia ulmoides extract and application thereof in treating osteoporosis | |
| CN109498771B (en) | Targeting composition for improving mild cognitive dysfunction and preparation method thereof | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN114177247A (en) | Anticancer blood sugar-controlling inonotus obliquus pure powder tablet and preparation method and application thereof | |
| CN1231224C (en) | Sealwort polysaccharide konjaku glucomannan capsule | |
| CN102233056A (en) | Chinese medicine composition for treating diabetes and syndromes of diabetes | |
| CN101596224A (en) | A kind of new purposes of penthorum chinense pursh extract | |
| CN100341547C (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN1284548C (en) | Preparation technology of supplementing kind capsule | |
| CN112716990A (en) | Sunflower disc extract, medicine containing sunflower disc extract, preparation method and application | |
| CN1692922A (en) | Medicine composite used for lowering blood-sugar, prepn. method and use thereof | |
| CN108578578A (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN111437287A (en) | Application of durian peel polysaccharide in preparation of immunopotentiating drugs | |
| CN101804128B (en) | Medicine composition, and use thereof in preparing medicine for curing inflammatory enteropathy | |
| CN1456309A (en) | Antilipemic antiatherosclerosis medicine composition and preparing method, application thereof | |
| CN115154508B (en) | Preparation method and application of traditional Chinese medicine compound nanoparticles | |
| CN1280010A (en) | Oral medicine for curing diabetes and its producing method | |
| CN1245199C (en) | Oral medicinal composition for treating diabetes | |
| CN1289108C (en) | Chinese medicine preparation for treating senile dementia and preparation thereof | |
| CN115381874B (en) | Traditional Chinese medicine composition and granule for treating chicken noninfectious diarrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051214 Termination date: 20111030 |